16 completed, 10 recruiting, 4 terminated, 3 active not recruiting. 13 Phase 2, 5 Phase 3, 2 Not applicable, 2 Phase 1, 2 Phase 4.
Follow Nephritis, Hereditary: new trials by email Literature Review of Nephritis, Hereditary trials Research Report on Nephritis, Hereditary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT) Antiphospholipid (aPL)-Positive, Rheumatic Arthritis | Not yet recruiting | Axiom Bioregistry | 5000 | 2026-10-18 | 2026-10-23 | |
| EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety Exaluren - Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive | Phase 2 | Recruiting | Eloxx Pharmaceuticals, Inc. | 24 | 2026-06-30 | 2026-09-30 |
| Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE) Observational assessment - Periodontal Disease, Periodontitis | Recruiting | Stefan Lujinschi | 100 | 2026-05-04 | 2026-06-26 | |
| A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome BAY 3401016, Placebo - Alport Syndrome | Phase 2 | Active not recruiting | Bayer | 60 | 2025-11-19 | 2026-09-18 |
| Human Umbilical Cord Mesenchymal Stem Cells for Alport Syndrome hUC-MSC, Placebo control drug - Alport Syndrome | Phase 2 / Phase 3 | Not yet recruiting | Guangzhou Women and Children's Medical Center | 40 | 2025-01-01 | 2024-12-31 |
| Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1) Vonafexor - Alport Syndrome | Phase 2 | Completed | Enyo Pharma | 26 | 2024-08-01 | 2026-02-09 |
| Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients Dapagliflozin, Placebo - Chronic Kidney Failure in Children and Young Adults | Phase 3 | Recruiting | University Hospital Goettingen | 102 | 2024-03-25 | 2026-10-16 |
| Albuminuria Lowering Effect of Dapagliflozin, Spironolactone and Their Combination in Adult Patients With Alport Syndrome (COMBINE-ALPORT) Treatment with Spironolactone followed by Dapagliflozin followed by their combination, Treatment with Dapagliflozin followed by Spironolactone followed by their combination - Alport Syndrome, Thin Basement Membrane Disease | Phase 4 | Completed | Stefan Lujinschi | 12 | 2024-02-26 | 2026-06-25 |
| A Study to Evaluate Setanaxib in Patients With Alport Syndrome Setanaxib, Placebo - Alport Syndrome | Phase 1 / Phase 2 | Completed | Calliditas Therapeutics AB | 20 | 2023-11-27 | 2026-04-13 |
| Effects of Dapagliflozin on Progression of Alport Syndrome Dapagliflozin 10mg Tab - Alport Syndrome | Unknown | Nanjing University School of Medicine | 222 | 2023-11-15 | 2024-09-05 | |
| ASF Alport Patient Registry Longitudinal data collection - Alport Syndrome, Thin Basement Membrane Disease | Recruiting | Alport Syndrome Foundation | 2500 | 2023-08-24 | 2026-04-14 | |
| Treatment With Metformin in Chinese Children With Alport Syndrome Metformin, Placebo - Alport Syndrome, Metformin | Phase 4 | Unknown | Peking University First Hospital | 78 | 2023-01-03 | 2022-12-19 |
| A Study of ELX-02 in Patients With Alport Syndrome ELX-02 - Alport Syndrome | Phase 2 | Completed | Eloxx Pharmaceuticals, Inc. | 3 | 2022-11-28 | 2026-02-24 |
| Baby Detect : Genomic Newborn Screening Congenital Adrenal Hyperplasia, Familial Hyperinsulinemic Hypoglycemia 1 | Completed | Centre Hospitalier Universitaire de Liege | 6824 | 2022-09-01 | 2025-08-12 | |
| Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis R3R01 - Alport Syndrome, Focal Segmental Glomerulosclerosis | Phase 2 | Completed | River 3 Renal Corp. | 43 | 2022-06-15 | 2025-09-29 |
| NEPTUNE Match Study Communication - Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis | Not applicable | Recruiting | University of Michigan | 375 | 2022-05-02 | 2026-06-10 |
| Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants Ramipril - Alport Syndrome | Not applicable | Not yet recruiting | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 510 | 2022-01-01 | 2021-11-24 |
| Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS) Hydroxychloroquine Sulfate 100 milligram (mg) Tab, Benazepril hydrochloride 10 milligram (mg) Tab - Alport Syndrome, X-Linked | Phase 2 | Completed | Shanghai Children's Hospital | 50 | 2021-09-08 | 2026-03-02 |
| Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases Sparsentan - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | Travere Therapeutics, Inc. | 67 | 2021-08-12 | 2026-05-12 |
| Atrasentan in Patients With Proteinuric Glomerular Diseases Atrasentan - IgA Nephropathy, Focal Segmental Glomerulosclerosis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 103 | 2021-03-15 | 2026-06-01 |
Showing 20 of 38. Sign in to see all of them.
Kidney Diseases (7) · Glomerulosclerosis, Focal Segmental (6) · Hematuria, Benign Familial (4) · Renal Insufficiency, Chronic (4) · Anemia, Sickle Cell (3) · Cystinosis (3) · Glomerulonephritis, IGA (3) · Glomerulonephritis, Membranous (3) · Glycogen Storage Disease Type II (3) · Nephrosis, Lipoid (3) · Pseudohypoaldosteronism (3) · 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (2) · Acidemia, isovaleric (2) · Adenine phosphoribosyltransferase deficiency (2)
Collagen Diseases (38) · Congenital Abnormalities (38) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (38) · Connective Tissue Diseases (38) · Female Urogenital Diseases (38) · Female Urogenital Diseases and Pregnancy Complications (38) · Male Urogenital Diseases (38) · Skin and Connective Tissue Diseases (38) · Urogenital Abnormalities (38) · Urogenital Diseases (38) · Urologic Diseases (38) · Nephritis (36) · Kidney Diseases (31) · Pathological Conditions, Signs and Symptoms (11) · Pathologic Processes (9)
Hydroxymethylglutaryl-CoA Reductase Inhibitors (2) · Ramipril (2) · bardoxolone methyl (2) · benazepril (2) · dapagliflozin (2) · Angiotensin Receptor Antagonists (1) · Angiotensin-Converting Enzyme Inhibitors (1) · Atrasentan (1) · ELX-02 (1) · Fluvastatin (1) · Metformin (1) · Sodium-Glucose Transporter 2 Inhibitors (1) · Spironolactone (1) · Tablets (1) · Therapeutics (1)
University of Minnesota (4) · Genzyme, a Sanofi Company (3) · Biogen (2) · Eloxx Pharmaceuticals, Inc. (2) · Novartis Pharmaceuticals (2) · Stefan Lujinschi (2) · University Hospital Goettingen (2) · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (2) · Alport Syndrome Foundation (1) · Axiom Bioregistry (1) · Bayer (1) · CENTOGENE GmbH Rostock (1) · Calliditas Therapeutics AB (1) · Centre Hospitalier Universitaire de Liege (1) · Enyo Pharma (1)
United States (18) · United Kingdom (11) · France (9) · Germany (9) · Spain (8) · Australia (6) · China (6) · Italy (4) · Japan (3) · Romania (3) · Belgium (2) · Canada (2) · Czechia (2) · India (2) · Netherlands (2)
Clifford E Kashtan, MD (3) · Oliver Gross, MD (2) · Bahtiar Ismail, MD, PhD (1) · Bradley Warady, MD (1) · Clifford Kashtan, MD (1) · Curt Scharfe, MD, PhD (1) · Erica Daina, MD (1) · Gener Ismail, Professor, MD, PhD (1) · Laurence Heidet, PHD (1) · Laurent Servais (1) · Makabe Aberle, BS (1) · Matthias Kretzler, MD (1)
PMID 40938675, PMID 33159213, PMID 38724717, PMID 22166847, PMID 22237748, PMID 22997344, PMID 24529291, PMID 27402170, PMID 30691124, PMID 31315600, PMID 32299679, PMID 33040356, PMID 33772369, PMID 33789284, PMID 34359984, PMID 35022790, PMID 35142618, PMID 36411058, PMID 37254256, PMID 38308509, PMID 38829703, PMID 39122650, PMID 39698346, PMID 39899371, PMID 41442197, PMID 42384439
2018 (1), 2019 (1), 2023 (1), R01DK141114 (1), U54DK083912 (1)